טוען...
Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation
BACKGROUND: Ex-vivo lung perfusion (EVLP) is an innovative platform for assessing donor lungs in the pre-transplant window. In this study, we demonstrate an extension of its utility by administering the anti-CD20 monoclonal antibody, Rituximab, during EVLP. We hypothesized that this would lead to ta...
שמור ב:
| הוצא לאור ב: | EBioMedicine |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501077/ https://ncbi.nlm.nih.gov/pubmed/32950000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102994 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|